公开(公告)号：US20190160170A1

公开(公告)日：2019-05-30

申请号：US16270317

申请日：2019-02-07

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  C07K16/30

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US09492565B2

公开(公告)日：2016-11-15

申请号：US14854613

申请日：2015-09-15

Applicant: GENMAB A/S

Inventor： David Satijn ,  Sandra Verploegen ,  Wim Bleeker ,  Steen Lisby ,  Jan Van De Winkel ,  Patrick Van Berkel ,  Paul Parren

IPC: A61K39/395 ,  A61K47/48 ,  C07K16/36 ,  A61K45/06 ,  C07K16/30

CPC classification number: A61K47/48561 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/30 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.

Abstract translation: 针对组织因子的抗体药物偶联物。 还公开了包含抗体和抗体药物共轭物的药物组合物，以及使用抗体和抗体药物偶联物的治疗和诊断方法。

公开(公告)号：US11970544B2

公开(公告)日：2024-04-30

申请号：US17353087

申请日：2021-06-21

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

CPC classification number: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/565

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11866514B2

公开(公告)日：2024-01-09

申请号：US16777053

申请日：2020-01-30

Applicant: GENMAB A/S

Inventor： Aran Frank Labrijn ,  Joyce I. Meesters ,  Ewald T. J. Van Den Bremer ,  Joost J. Neijssen ,  Patrick Van Berkel ,  Bart De Goeij ,  Tom Vink ,  Jan Van De Winkel ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/46 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/40 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/468 ,  C07K16/1063 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/40 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

公开(公告)号：US20230027394A1

公开(公告)日：2023-01-26

申请号：US17739934

申请日：2022-05-09

Applicant: GENMAB A/S

Inventor： Rik RADEMAKER ,  Isil Altintas ,  Patrick Engelberts ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  C07K16/32

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US11230604B2

公开(公告)日：2022-01-25

申请号：US15909540

申请日：2018-03-01

Applicant: GENMAB A/S

Inventor： Michel De Weers ,  Tim Walseth ,  Jan Van De Winkel ,  Tom Vink ,  Paul Parren

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/573

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20200317799A1

公开(公告)日：2020-10-08

申请号：US16689361

申请日：2019-11-20

Applicant: Genmab A/S

Inventor： Jessica Teeling ,  Sigrid Ruuls ,  Martin Glennie ,  Jan G.J. van de Winkel ,  Paul Parren ,  Jørgen Petersen ,  Ole Baadsgaard ,  Haichun Huang

IPC: C07K16/28 ,  C07K16/42 ,  A61K39/395 ,  A61K45/06 ,  G01N33/68

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US10512688B2

公开(公告)日：2019-12-24

申请号：US15325364

申请日：2015-07-10

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  A61K39/00 ,  C07K16/30

Abstract: The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20180194849A1

公开(公告)日：2018-07-12

申请号：US15538419

申请日：2016-01-08

Applicant: BIONTECH AG ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US10000570B2

公开(公告)日：2018-06-19

申请号：US14739768

申请日：2015-06-15

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jan Van De Winkel ,  Janine Schuurman ,  Ignace Lasters

IPC: C07K16/28 ,  C07K16/00 ,  A61K39/395 ,  A61K47/48 ,  A61K51/10 ,  A61K39/00

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.